Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price Target
Needham Reiterates Buy on TScan Therapeutics, Maintains $6 Price Target
TScan Says Cancer Therapy Data Support Move to Phase 3 Trial
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
TScan Therapeutics Partners With Cellares To Evaluate Automated Clinical Manufacturing Of TSC-101, The Company's Lead TCR-T Therapy Candidate For Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate, Sales $982.000K Miss $2.500M Estimate
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space
Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Earnings Breakdown: TScan Therapeutics Q4
TScan Therapeutics' Cash And Cash Equivalents Of $152.4M To Provide Cash Runway Into 2H Of 2027
TScan Therapeutics Q4 2025 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M Estimate
TScan Therapeutics Q4 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M Estimate
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
TScan Therapeutics Completes Enrollment Into Cohort C Of ALLOHA Study
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.